Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Unknown 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1Breast 1

Conditions

Breast Neoplasms 1786Triple Negative Breast Neoplasms 298Ovarian Neoplasms 136Colorectal Neoplasms 118Lung Neoplasms 116Neoplasms 106Prostatic Neoplasms 103Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 83Pancreatic Neoplasms 80Melanoma 74Endometrial Neoplasms 65Head and Neck Neoplasms 60Uterine Cervical Neoplasms 57Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 44Carcinoma, Intraductal, Noninfiltrating 41Sarcoma 40Motor Activity 38Urinary Bladder Neoplasms 34Liver Neoplasms 33HER2-positive Breast Cancer 32Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 26Lymphedema 25Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

pembrolizumab 1olaparib 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fanconi Anemia, Complementation Group D1 × Breast × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡